- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05564390
MyeloMATCH MSRP: Eine Screening-Studie, um Menschen mit myeloischem Krebs einer Behandlungsstudie zuzuweisen
Master Screening and Reassessment Protocol (MSRP) für die NCI MyeloMATCH Clinical Trials
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Arzneimittel: Cytarabine
- Arzneimittel: Gemtuzumab Ozogamicin
- Verfahren: Bone Marrow Biopsy
- Biologisch: Epoetin Alfa
- Verfahren: Computed Tomography
- Verfahren: Echocardiography Test
- Verfahren: Multigated Acquisition Scan
- Verfahren: Biopsy Procedure
- Verfahren: Positron Emission Tomography
- Verfahren: Bone Marrow Aspiration
- Arzneimittel: Daunorubicin
- Arzneimittel: Daunorubicin Hydrochloride
- Arzneimittel: Busulfan
- Arzneimittel: Venetoclax
- Arzneimittel: Fludarabine
- Arzneimittel: Decitabine and Cedazuridine
- Arzneimittel: Placebo Administration
- Arzneimittel: Azacitidine
- Arzneimittel: Liposome-encapsulated Daunorubicin-Cytarabine
- Verfahren: Biospecimen Collection
- Arzneimittel: Enasidenib
- Biologisch: Luspatercept
- Biologisch: Emavusertib
- Arzneimittel: Gilteritinib
- Arzneimittel: Olutasidenib
- Sonstiges: Best Practice
- Arzneimittel: Quizartinib
- Verfahren: Allogeneic Hematopoietic Stem Cell Transplantation
- Verfahren: Chest Radiography
- Arzneimittel: Melphalan
- Strahlung: Total-Body Irradiation
- Verfahren: Mutation Carrier Screening
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. Screening and Reassessment (MSRP): To evaluate the feasibility of MATCHBox receiving and organizing all data needed for assignment to a myeloMATCH clinical trial or Tier Advancement Pathway (TAP) within 72 hours of MDNet receipt of all required specimens for initial therapy and within 10 days for subsequent therapy.
II. Tier Advancement Pathway (TAP): To enable participants who are not matched to an investigational myeloMATCH treatment substudy to receive standard of care (SOC) while remaining on the MSRP to maintain access to later tiers of treatment substudies.
SECONDARY OBJECTIVES:
I. Screening and Reassessment (MSRP):
Ia. To describe the time to generation of all data required for treatment substudy (or TAP) assignment, time to treatment substudy (or TAP) assignment, percent assigned to a myeloMATCH treatment substudy, and the percent of screened participants who register to a myeloMATCH investigational treatment substudy or are assigned to TAP:
Iai. Separately within each tier of myeloMATCH treatment substudy and analogous TAP assignment; Ibi. Separately within each clinical basket of myeloMATCH treatment substudies; Ici. Over time, across and within the categories above.
II. Tier Advancement Pathway (TAP):
IIa. To evaluate participants for assignment to higher tier treatment substudies within myeloMATCH; IIb. To describe, within tier- and basket- levels of TAP, measurable residual disease (MRD) rates and clonal evolution; IIc. To describe, within tier- and basket- levels of TAP, remission status and overall survival of participants who receive standard of care therapy; IId. To obtain MDNet specimens for translational medicine and biobanking.
OUTLINE:
REGISTRATION: Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a specific substudy containing a therapy targeted to the patient's mutational profile. If there is no targetable mutation, the patient is placed on a substudy testing novel combinations that do not contain a target-specific drug. Patients who are not eligible for any MYELOMATCH substudy are assigned to TAP.
TAP: Patients continue SOC treatment and undergo continued bone marrow aspiration and blood collection for possible future substudy assignment.
TREATMENT: Patients are assigned to a specific treatment substudy.
MM1YA-CTG01: Younger patients (age 18-59 years) with intermediate risk acute myeloid leukemia (AML) are randomized to 1 of 3 arms.
ARM I: Patients receive daunorubicin intravenously (IV) on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax orally (PO) once daily (QD) on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening.
ARM II: Patients receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.
ARM III: Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.
MM1YA-S01: Younger patients (age 18-59 years) with high-risk AML are randomized to 1 of 5 arms.
ARM I: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM II: Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM III: Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM IV: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
ARM V: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial.
MM2YA-EA01: Younger patients (age 18-59 years) with AML or secondary AML who have completed a tier 1 MyeloMATCH treatment study with complete remission (CR) or CR with partial hematologic recovery (CRh) and have detectable minimal residual disease (MRD) (> 0.1%) are randomized to 1 of 4 arms.
ARM A: Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
ARM B: Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
ARM C: Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
ARM D: Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
MM1OA-EA02: Patients are randomized to 1 of 3 regimens.
REGIMEN 1:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
REGIMEN 2:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
REGIMEN 3:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
MM1MDS-A01: Patients are randomized to 1 of 2 regimens.
REGIMEN 1: Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 1. Patients who experience CR, PR, or stable disease (SD) any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
REGIMEN 2: Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
MM1OA-S03: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
ARM 2: Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
MM1YA-A04: Patients are randomized to 1 of 2 regimens.
REGIMEN 1: Patients receive gemtuzumab ozogamicin IV on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study.
REGIMEN 2: Patients receive venetoclax PO QD on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study.
MM3TCT-A03: Patients with matched donors are randomized to conditioning 1A or 1B. Patients with haploidentical or mismatched unrelated donors are randomized to conditioning 2A or 2B.
CONDITIONING 1A: Patients receive venetoclax PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or twice daily (BID) on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
CONDITIONING 1B: Patients receive placebo PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
CONDITIONING 2A: Patients receive venetoclax PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
CONDITIONING 2B: Patients receive placebo PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity.
MAINTENANCE: All patients without evidence of relapse at day +100 are re-randomized to maintenance I or II.
MAINTENANCE I: Patients receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity.
MAINTENANCE II: Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity.
Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo positron emission tomography (PET) scan and/or computed tomography (CT) scan throughout the study.
MM1OA-MDS-A05: Patients are assigned to 1 of 3 cohorts.
COHORT A: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive ASTX727 PO QD on days 1-5 of each cycle and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
ARM 2: Patients receive ASTX727 PO QD on days 1-5 of each cycle, venetoclax PO QD on days 1-28 of each cycle, and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
COHORT B: Patients are randomized to 1 of 2 arms.
ARM 3: Patients receive ASTX727 PO QD on days 1-5 of each cycle and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
ARM 4: Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients without CR after cycle 6 may then cross-over to Arm 3. Patients with CR, as well as patients without CR but deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
COHORT C: Patients receive olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial.
MM1MDS-CTG02: This is a dose-escalation study of luspatercept in combination, dependent upon arms assignments, with fixed dose epoetin alfa or emavusertib. Patients are randomized to 1 of 3 arms.
ARM 1: Patients receive luspatercept SC on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.
ARM 2: Patients receive luspatercept SC on day 1 and epoetin alfa SC once weekly (QW) for each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.
ARM 3: Patients receive luspatercept SC on day 1 and emavusertib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study.
MM1YA-EA05: Patients are randomized to 1 of 2 arms.
ARM A:
INDUCTION: Patients receive cytarabine IV, over 24 hours, on days 1-7, daunorubicin IV on days 1-3, and quizartinib PO QD on days 8-21 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspiration/biopsy. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts may repeat induction as described starting on day 28-45. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts proceed to consolidation, following count recovery, by 30 days post-confirmation of CR/CRi. Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts repeat the bone marrow aspiration/biopsy 1 week later and then either repeat induction or proceed to consolidation, based on results. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts proceed to consolidation.
CONSOLIDATION: Patients receive cytarabine IV, over 1-3 hours, every 12 hours on days 1, 3 and 5 and quizartinib PO QD on days 6-19 in the absence of disease progression or unacceptable toxicity.
ARM B:
CYCLE 1: Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9, venetoclax PO QD on days 1-28, and quizartinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity and based on bone marrow findings. Patients undergo bone marrow aspiration/biopsy on day 14 of cycle 1. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts continue treatment as described through day 28 of cycle 1 and then proceed to cycle 2 without interruption or delay, as long as repeat bone marrow aspiration/biopsy on day 28 of cycle 1 is consistent with persistent blasts > 5%. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28) and then proceed to cycle 2 of treatment as described following count recovery. Patients without count recovery by day 42 undergo repeat bone marrow aspiration/biopsy. Patients with count recovery by day 42 proceed to cycle 2 (by day 50). For patients without count recovery by day 50 whose repeat bone marrow aspiration/biopsy shows no blasts, initiation of cycle 2 will be discussed with the study chairs. Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib, undergo repeat bone marrow aspiration/biopsy 1 week later, and proceed based on repeat biopsy results as described. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28) and then proceed to cycle 2 of treatment as described following count recovery. Patients without count recovery by day 42 undergo repeat bone marrow aspiration/biopsy. Patients with count recovery by day 42 proceed to cycle 2 (by day 50). For patients without count recovery by day 50 whose repeat bone marrow aspiration/biopsy shows no blasts, initiation of cycle 2 will be discussed with the study chairs.
CYCLE 2: Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9, venetoclax PO QD on days 1-28, and quizartinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity and based on bone marrow findings. Patients who do not achieve response after completion of cycle 1 undergo bone marrow aspiration/biopsy on day 14 of cycle 2. Patients with ≥ 20% bone marrow cellularity and > 5% bone marrow leukemic blasts continue venetoclax and quizartinib as described through day 28 of cycle 2. Patients with ≥ 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28). Patients with < 20% bone marrow cellularity and > 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib, undergo repeat bone marrow aspiration/biopsy 1 week later, and proceed based on repeat aspiration/biopsy results as described. Patients with < 20% bone marrow cellularity and ≤ 5% bone marrow leukemic blasts interrupt venetoclax and quizartinib for the remainder of the cycle (through day 28).
Upon completion of two cycles of therapy on either Arm A or Arm B, patients who are eligible can proceed to allogeneic stem cell transplant; while awaiting allogeneic stem cell transplant, patients should continue standard of care therapy.
Patients undergo echocardiography or MUGA scan during screening and undergo bone marrow aspiration and biopsy as well as blood sample collection throughout the study.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 5G2
- Rekrutierung
- Arthur J E Child Comprehensive Cancer Centre
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Hauptermittler:
- Mary L. Savoie
-
Edmonton, Alberta, Kanada, T6G 2B7
- Rekrutierung
- University of Alberta Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 780-407-8798
- E-Mail: pedsoncologyresearch@ahs.ca
-
Hauptermittler:
- Joseph M. Brandwein
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- Rekrutierung
- CancerCare Manitoba
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-561-1026
- E-Mail: ctu_web@cancercare.mb.ca
-
Hauptermittler:
- Brett L. Houston
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 2Y9
- Rekrutierung
- QEII Health Sciences Centre/Nova Scotia Health Authority
-
Kontakt:
- Site Public Contact
- Telefonnummer: 902-473-6000
-
Hauptermittler:
- Mahmoud Elsawy
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8V 5C2
- Rekrutierung
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 905-387-9495
-
Hauptermittler:
- Alejandro Garcia-Horton
-
Ottawa, Ontario, Kanada, K1H 8L6
- Rekrutierung
- Ottawa Hospital and Cancer Center-General Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 613-761-4395
-
Hauptermittler:
- Mitchell Sabloff
-
Toronto, Ontario, Kanada, M5G 2M9
- Suspendiert
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Kanada, M4N 3M5
- Rekrutierung
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
Kontakt:
- Site Public Contact
- Telefonnummer: 416-480-5000
-
Hauptermittler:
- Rena J. Buckstein
-
-
Quebec
-
Greenfield Park, Quebec, Kanada, J4V 2H1
- Rekrutierung
- CSSS Champlain-Charles Le Moyne
-
Kontakt:
- Site Public Contact
- Telefonnummer: 450-466-5065
-
Hauptermittler:
- Sami Morin-Ben Abdallah
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrutierung
- Jewish General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 8248 514-340-8222
-
Hauptermittler:
- Sarit E. Assouline
-
Montreal, Quebec, Kanada, H1T 2M4
- Rekrutierung
- CIUSSSEMTL-Hopital Maisonneuve-Rosemont
-
Hauptermittler:
- Julie Bergeron
-
Kontakt:
- Site Public Contact
- Telefonnummer: 3329 514-252-3400
-
-
-
-
-
San Juan, Puerto Rico, 00927
- Rekrutierung
- Centro Comprensivo de Cancer de UPR
-
Hauptermittler:
- Luis J. Santos Reyes
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
San Juan, Puerto Rico, 00936
- Rekrutierung
- San Juan City Hospital
-
Hauptermittler:
- Luis J. Santos Reyes
-
Kontakt:
- Site Public Contact
- Telefonnummer: 787-763-1296
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- Rekrutierung
- University of Alabama at Birmingham Cancer Center
-
Hauptermittler:
- Razan Mohty
-
Kontakt:
- Site Public Contact
- E-Mail: gingerreeves@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Rekrutierung
- Mayo Clinic Hospital in Arizona
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Hauptermittler:
- James M. Foran
-
Tucson, Arizona, Vereinigte Staaten, 85719
- Rekrutierung
- Banner University Medical Center - Tucson
-
Hauptermittler:
- Sharad Khurana
-
Kontakt:
- Site Public Contact
- E-Mail: UACC-IIT@uacc.arizona.edu
-
Tucson, Arizona, Vereinigte Staaten, 85719
- Rekrutierung
- University of Arizona Cancer Center-North Campus
-
Hauptermittler:
- Sharad Khurana
-
Kontakt:
- Site Public Contact
- E-Mail: UACC-IIT@uacc.arizona.edu
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- Rekrutierung
- University of Arkansas for Medical Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 501-686-8274
-
Hauptermittler:
- Ankur Varma
-
-
California
-
Berkeley, California, Vereinigte Staaten, 94704
- Aktiv, nicht rekrutierend
- Alta Bates Summit Medical Center-Herrick Campus
-
Dublin, California, Vereinigte Staaten, 94568
- Rekrutierung
- Kaiser Permanente Dublin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
-
Hauptermittler:
- Faisal N. Cheema
-
Fremont, California, Vereinigte Staaten, 94538
- Rekrutierung
- Kaiser Permanente-Fremont
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
Fresno, California, Vereinigte Staaten, 93720
- Suspendiert
- Kaiser Permanente-Fresno
-
Fresno, California, Vereinigte Staaten, 93720
- Rekrutierung
- Kaiser Permanente Fresno Orchard Plaza
-
Kontakt:
- Site Public Contact
- Telefonnummer: 833-574-2273
-
Hauptermittler:
- Faisal N. Cheema
-
Irvine, California, Vereinigte Staaten, 92612
- Rekrutierung
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Hauptermittler:
- Deepa Jeyakumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-8839
- E-Mail: ucstudy@uci.edu
-
Long Beach, California, Vereinigte Staaten, 90822
- Aktiv, nicht rekrutierend
- Tibor Rubin VA Medical Center
-
Los Angeles, California, Vereinigte Staaten, 90048
- Rekrutierung
- Cedars-Sinai Medical Center
-
Hauptermittler:
- Noah M. Merin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-423-2133
- E-Mail: Cancer.trial.info@cshs.org
-
Modesto, California, Vereinigte Staaten, 95356
- Suspendiert
- Kaiser Permanente-Modesto
-
Modesto, California, Vereinigte Staaten, 95356
- Rekrutierung
- Kaiser Permanente- Modesto MOB II
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
-
Hauptermittler:
- Faisal N. Cheema
-
Oakland, California, Vereinigte Staaten, 94611
- Rekrutierung
- Kaiser Permanente-Oakland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Hauptermittler:
- Deepa Jeyakumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-8839
- E-Mail: ucstudy@uci.edu
-
Roseville, California, Vereinigte Staaten, 95661
- Rekrutierung
- Kaiser Permanente-Roseville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
Sacramento, California, Vereinigte Staaten, 95817
- Rekrutierung
- University of California Davis Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 916-734-3089
-
Hauptermittler:
- Brian A. Jonas
-
Sacramento, California, Vereinigte Staaten, 95814
- Rekrutierung
- Kaiser Permanente Downtown Commons
-
Hauptermittler:
- Faisal N. Cheema
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: kpoct@kp.org
-
Sacramento, California, Vereinigte Staaten, 95823
- Rekrutierung
- Kaiser Permanente-South Sacramento
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
San Francisco, California, Vereinigte Staaten, 94115
- Rekrutierung
- Kaiser Permanente-San Francisco
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
San Francisco, California, Vereinigte Staaten, 94143
- Rekrutierung
- UCSF Medical Center-Parnassus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-3222
-
Hauptermittler:
- Timothy Ferng
-
San Jose, California, Vereinigte Staaten, 95119
- Rekrutierung
- Kaiser Permanente-Santa Teresa-San Jose
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
San Leandro, California, Vereinigte Staaten, 94577
- Rekrutierung
- Kaiser Permanente San Leandro
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
San Rafael, California, Vereinigte Staaten, 94903
- Rekrutierung
- Kaiser San Rafael-Gallinas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
Santa Clara, California, Vereinigte Staaten, 95051
- Rekrutierung
- Kaiser Permanente Medical Center - Santa Clara
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
Santa Rosa, California, Vereinigte Staaten, 95403
- Rekrutierung
- Kaiser Permanente-Santa Rosa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
South San Francisco, California, Vereinigte Staaten, 94080
- Rekrutierung
- Kaiser Permanente-South San Francisco
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
Vallejo, California, Vereinigte Staaten, 94589
- Rekrutierung
- Kaiser Permanente-Vallejo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
Walnut Creek, California, Vereinigte Staaten, 94596
- Rekrutierung
- Kaiser Permanente-Walnut Creek
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Rekrutierung
- Yale University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Jan P. Bewersdorf
-
West Haven, Connecticut, Vereinigte Staaten, 06516
- Rekrutierung
- Veterans Affairs Connecticut Healthcare System-West Haven Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 2832 203-937-3421
-
Hauptermittler:
- Alexander Pine
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610
- Rekrutierung
- UF Health Cancer Institute - Gainesville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 352-273-8010
-
Hauptermittler:
- Dina G. Khalaf
-
Jacksonville, Florida, Vereinigte Staaten, 32224-9980
- Rekrutierung
- Mayo Clinic in Florida
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Hauptermittler:
- James M. Foran
-
Miami, Florida, Vereinigte Staaten, 33176
- Rekrutierung
- Miami Cancer Institute
-
Hauptermittler:
- Firas El Chaer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 786-596-2000
-
Pembroke Pines, Florida, Vereinigte Staaten, 33028
- Rekrutierung
- Memorial Hospital West
-
Kontakt:
- Site Public Contact
- Telefonnummer: 954-265-4325
-
Hauptermittler:
- Yehuda E. Deutsch
-
Ruskin, Florida, Vereinigte Staaten, 33570
- Rekrutierung
- Moffitt Cancer Center at SouthShore
-
Hauptermittler:
- Rory M. Shallis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-679-0775
- E-Mail: ClinicalTrials@moffitt.org
-
Tampa, Florida, Vereinigte Staaten, 33607
- Rekrutierung
- Moffitt Cancer Center-International Plaza
-
Hauptermittler:
- Rory M. Shallis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-679-0775
- E-Mail: ClinicalTrials@moffitt.org
-
Tampa, Florida, Vereinigte Staaten, 33612
- Rekrutierung
- Moffitt Cancer Center - McKinley Campus
-
Hauptermittler:
- Rory M. Shallis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-679-0775
- E-Mail: ClinicalTrials@moffitt.org
-
Tampa, Florida, Vereinigte Staaten, 33612
- Rekrutierung
- Moffitt Cancer Center
-
Hauptermittler:
- Rory M. Shallis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-679-0775
- E-Mail: ClinicalTrials@moffitt.org
-
Wesley Chapel, Florida, Vereinigte Staaten, 33544
- Rekrutierung
- Moffitt Cancer Center at Wesley Chapel
-
Hauptermittler:
- Rory M. Shallis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-679-0775
- E-Mail: ClinicalTrials@moffitt.org
-
-
Georgia
-
Albany, Georgia, Vereinigte Staaten, 31701
- Rekrutierung
- Phoebe Putney Memorial Hospital
-
Hauptermittler:
- Vamsi Kota
-
Kontakt:
- Site Public Contact
- Telefonnummer: 229-312-0405
- E-Mail: ga_cares@augusta.edu
-
Augusta, Georgia, Vereinigte Staaten, 30912
- Rekrutierung
- Augusta University Medical Center
-
Hauptermittler:
- Vamsi Kota
-
Kontakt:
- Site Public Contact
- Telefonnummer: 706-721-2388
- E-Mail: ga_cares@augusta.edu
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Rekrutierung
- Kapiolani Medical Center for Women and Children
-
Hauptermittler:
- Craig S. Boddy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-983-6090
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Rekrutierung
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Hauptermittler:
- Craig S. Boddy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-524-6115
- E-Mail: i.webster@hawaiicancercare.com
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Rekrutierung
- Straub Clinic and Hospital
-
Hauptermittler:
- Craig S. Boddy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-522-4333
-
Honolulu, Hawaii, Vereinigte Staaten, 96819
- Rekrutierung
- Kaiser Permanente Moanalua Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-432-5195
- E-Mail: shelley.a.clark@kp.org
-
Hauptermittler:
- Faisal N. Cheema
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Rekrutierung
- Hawaii Cancer Care - Westridge
-
Hauptermittler:
- Craig S. Boddy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-539-2273
- E-Mail: info@hawaiicancercare.com
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Rekrutierung
- Pali Momi Medical Center
-
Hauptermittler:
- Craig S. Boddy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-486-6000
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- Rekrutierung
- Saint Luke's Cancer Institute - Boise
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Hauptermittler:
- Charles W. Drescher
-
Boise, Idaho, Vereinigte Staaten, 83706
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Boise
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-3671
- E-Mail: stephanie.couch@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Caldwell, Idaho, Vereinigte Staaten, 83605
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Caldwell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-3671
- E-Mail: stephanie.couch@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
- Rekrutierung
- Kootenai Health - Coeur d'Alene
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Fruitland, Idaho, Vereinigte Staaten, 83619
- Rekrutierung
- Saint Luke's Cancer Institute - Fruitland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Hauptermittler:
- Charles W. Drescher
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Rekrutierung
- Saint Luke's Cancer Institute - Meridian
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Hauptermittler:
- Charles W. Drescher
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Rekrutierung
- Saint Luke's Cancer Institute - Nampa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Hauptermittler:
- Charles W. Drescher
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Nampa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Post Falls, Idaho, Vereinigte Staaten, 83854
- Rekrutierung
- Kootenai Clinic Cancer Services - Post Falls
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Vereinigte Staaten, 83864
- Rekrutierung
- Kootenai Clinic Cancer Services - Sandpoint
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
-
Illinois
-
Aurora, Illinois, Vereinigte Staaten, 60506
- Rekrutierung
- Advocate Outpatient Center - Aurora
-
Hauptermittler:
- Thomas J. Saphner
-
Kontakt:
- Site Public Contact
- E-Mail: ncorp@aah.org
-
Barrington, Illinois, Vereinigte Staaten, 60010
- Rekrutierung
- Advocate Good Shepherd Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-842-4847
-
Hauptermittler:
- Thomas J. Saphner
-
Bloomington, Illinois, Vereinigte Staaten, 61704
- Rekrutierung
- Illinois CancerCare-Bloomington
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Bloomington, Illinois, Vereinigte Staaten, 61701
- Rekrutierung
- OSF Saint Joseph Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Canton, Illinois, Vereinigte Staaten, 61520
- Rekrutierung
- Illinois CancerCare-Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Carthage, Illinois, Vereinigte Staaten, 62321
- Rekrutierung
- Illinois CancerCare-Carthage
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- University of Chicago Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-702-8222
- E-Mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hauptermittler:
- Olatoyosi M. Odenike
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Northwestern University
-
Hauptermittler:
- Jessica K. Altman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-695-1301
- E-Mail: cancer@northwestern.edu
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rekrutierung
- University of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Hauptermittler:
- Noah Birch
-
Chicago, Illinois, Vereinigte Staaten, 60657
- Rekrutierung
- Advocate Illinois Masonic Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-296-5360
-
Hauptermittler:
- Thomas J. Saphner
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rekrutierung
- Rush MD Anderson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-226-2371
- E-Mail: Cancer_Studies@rush.edu
-
Hauptermittler:
- Melissa L. Larson
-
Crystal Lake, Illinois, Vereinigte Staaten, 60014
- Rekrutierung
- AMG Crystal Lake - Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocate.com
-
Hauptermittler:
- Thomas J. Saphner
-
Danville, Illinois, Vereinigte Staaten, 61832
- Rekrutierung
- Carle at The Riverfront
-
Hauptermittler:
- Suparna Mantha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@Carle.com
-
DeKalb, Illinois, Vereinigte Staaten, 60115
- Rekrutierung
- Northwestern Medicine Cancer Center Kishwaukee
-
Hauptermittler:
- Jessica K. Altman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-352-5360
- E-Mail: Donald.Smith3@nm.org
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Rekrutierung
- Cancer Care Specialists of Illinois - Decatur
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Rekrutierung
- Decatur Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Dixon, Illinois, Vereinigte Staaten, 61021
- Rekrutierung
- Illinois CancerCare-Dixon
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 815-285-7800
-
Downers Grove, Illinois, Vereinigte Staaten, 60515
- Rekrutierung
- Advocate Good Samaritan Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-275-1270
- E-Mail: Barbara.barhamand@advocatehealth.com
-
Hauptermittler:
- Thomas J. Saphner
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Carle Physician Group-Effingham
-
Hauptermittler:
- Suparna Mantha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Crossroads Cancer Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, Vereinigte Staaten, 60123
- Rekrutierung
- Advocate Sherman Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-429-2907
-
Hauptermittler:
- Thomas J. Saphner
-
Eureka, Illinois, Vereinigte Staaten, 61530
- Rekrutierung
- Illinois CancerCare-Eureka
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Evanston, Illinois, Vereinigte Staaten, 60201
- Rekrutierung
- NorthShore University HealthSystem-Evanston Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Hauptermittler:
- Robert M. Eisner
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Rekrutierung
- Illinois CancerCare-Galesburg
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Geneva, Illinois, Vereinigte Staaten, 60134
- Rekrutierung
- Northwestern Medicine Cancer Center Delnor
-
Hauptermittler:
- Jessica K. Altman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-352-5360
- E-Mail: Donald.Smith3@nm.org
-
Glenview, Illinois, Vereinigte Staaten, 60026
- Rekrutierung
- NorthShore University HealthSystem-Glenbrook Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Hauptermittler:
- Robert M. Eisner
-
Glenview, Illinois, Vereinigte Staaten, 60026
- Rekrutierung
- Northwestern Medicine Glenview Outpatient Center
-
Hauptermittler:
- Jessica K. Altman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-695-1102
-
Grayslake, Illinois, Vereinigte Staaten, 60030
- Rekrutierung
- Northwestern Medicine Grayslake Outpatient Center
-
Hauptermittler:
- Jessica K. Altman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-695-1102
-
Harvey, Illinois, Vereinigte Staaten, 60426
- Rekrutierung
- Ingalls Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-915-4673
- E-Mail: clinicaltrials@ingalls.org
-
Hauptermittler:
- Kimberly R. Kruczek
-
Hazel Crest, Illinois, Vereinigte Staaten, 60429
- Rekrutierung
- Advocate South Suburban Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-799-9995
-
Hauptermittler:
- Thomas J. Saphner
-
Highland Park, Illinois, Vereinigte Staaten, 60035
- Rekrutierung
- NorthShore University HealthSystem-Highland Park Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Hauptermittler:
- Robert M. Eisner
-
Hines, Illinois, Vereinigte Staaten, 60141
- Rekrutierung
- Edward Hines Jr VA Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-202-8387
-
Hauptermittler:
- Jorgena Kosti-Schwartz
-
Kewanee, Illinois, Vereinigte Staaten, 61443
- Rekrutierung
- Illinois CancerCare-Kewanee Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Lake Forest, Illinois, Vereinigte Staaten, 60045
- Rekrutierung
- Northwestern Medicine Lake Forest Hospital
-
Hauptermittler:
- Jessica K. Altman
-
Kontakt:
- Site Public Contact
- E-Mail: cancertrials@northwestern.edu
-
Libertyville, Illinois, Vereinigte Staaten, 60048
- Rekrutierung
- AMG Libertyville - Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocatehealth.com
-
Hauptermittler:
- Thomas J. Saphner
-
Libertyville, Illinois, Vereinigte Staaten, 60048
- Rekrutierung
- Condell Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocatehealth.com
-
Hauptermittler:
- Thomas J. Saphner
-
Macomb, Illinois, Vereinigte Staaten, 61455
- Rekrutierung
- Illinois CancerCare-Macomb
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Rekrutierung
- Carle Physician Group-Mattoon/Charleston
-
Hauptermittler:
- Suparna Mantha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Rekrutierung
- Loyola University Medical Center
-
Hauptermittler:
- Stephanie B. Tsai
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-226-4357
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- Cancer Care Center of O'Fallon
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, Vereinigte Staaten, 60453-2699
- Rekrutierung
- Advocate Christ Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-323-8622
-
Hauptermittler:
- Thomas J. Saphner
-
Oak Lawn, Illinois, Vereinigte Staaten, 60453
- Rekrutierung
- Advocate Outpatient Center - Oak Lawn
-
Hauptermittler:
- Thomas J. Saphner
-
Kontakt:
- Site Public Contact
- E-Mail: ncorp@aah.org
-
Orland Park, Illinois, Vereinigte Staaten, 60462
- Rekrutierung
- Northwestern Medicine Orland Park
-
Hauptermittler:
- Jessica K. Altman
-
Kontakt:
- Site Public Contact
- E-Mail: nctnprogram_rhlccc@northwestern.edu
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Rekrutierung
- Illinois CancerCare-Ottawa Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Palos Heights, Illinois, Vereinigte Staaten, 60463
- Rekrutierung
- Advocate High Tech Medical Park
-
Hauptermittler:
- Thomas J. Saphner
-
Kontakt:
- Site Public Contact
- E-Mail: ncorp@aah.org
-
Park Ridge, Illinois, Vereinigte Staaten, 60068
- Rekrutierung
- Advocate Lutheran General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-384-3621
-
Hauptermittler:
- Thomas J. Saphner
-
Pekin, Illinois, Vereinigte Staaten, 61554
- Rekrutierung
- Illinois CancerCare-Pekin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Rekrutierung
- Illinois CancerCare-Peoria
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Peoria, Illinois, Vereinigte Staaten, 61636
- Rekrutierung
- Methodist Medical Center of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Peoria, Illinois, Vereinigte Staaten, 61637
- Rekrutierung
- OSF Saint Francis Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Peru, Illinois, Vereinigte Staaten, 61354
- Rekrutierung
- Illinois CancerCare-Peru
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Princeton, Illinois, Vereinigte Staaten, 61356
- Rekrutierung
- Illinois CancerCare-Princeton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Southern Illinois University School of Medicine
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Springfield Clinic
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-444-7541
-
Springfield, Illinois, Vereinigte Staaten, 62781
- Rekrutierung
- Springfield Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-528-7541
- E-Mail: pallante.beth@mhsil.com
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Rekrutierung
- Carle Cancer Center
-
Hauptermittler:
- Suparna Mantha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Warrenville, Illinois, Vereinigte Staaten, 60555
- Rekrutierung
- Northwestern Medicine Cancer Center Warrenville
-
Hauptermittler:
- Jessica K. Altman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-352-5360
- E-Mail: Donald.Smith3@nm.org
-
Washington, Illinois, Vereinigte Staaten, 61571
- Rekrutierung
- Illinois CancerCare - Washington
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-243-3605
- E-Mail: andersonj@illinoiscancercare.com
-
Hauptermittler:
- Bryan A. Faller
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Rekrutierung
- Indiana University/Melvin and Bren Simon Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 317-278-5632
- E-Mail: iutrials@iu.edu
-
Hauptermittler:
- Rita Assi
-
-
Iowa
-
Ankeny, Iowa, Vereinigte Staaten, 50023
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Clive, Iowa, Vereinigte Staaten, 50325
- Rekrutierung
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Rekrutierung
- Mercy Medical Center - Des Moines
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Richard L. Deming
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Rekrutierung
- Iowa Methodist Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-6727
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- Rekrutierung
- University of Iowa/Holden Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-237-1225
-
Hauptermittler:
- Prajwal Dhakal
-
Pella, Iowa, Vereinigte Staaten, 50219
- Rekrutierung
- UI Healthcare Mission Cancer and Blood - Pella
-
Hauptermittler:
- Seema Harichand-Herdt
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-282-2921
- E-Mail: trials@missioncancer.com
-
Waukee, Iowa, Vereinigte Staaten, 50263
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
West Des Moines, Iowa, Vereinigte Staaten, 50266
- Rekrutierung
- The Iowa Clinic PC
-
Hauptermittler:
- Seema Harichand-Herdt
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-875-9815
-
-
Kansas
-
Fairway, Kansas, Vereinigte Staaten, 66205
- Rekrutierung
- University of Kansas Clinical Research Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Hauptermittler:
- Tara L. Lin
-
Hays, Kansas, Vereinigte Staaten, 67601
- Rekrutierung
- HaysMed
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-623-5774
-
Hauptermittler:
- Tara L. Lin
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Rekrutierung
- University of Kansas Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Hauptermittler:
- Tara L. Lin
-
Lawrence, Kansas, Vereinigte Staaten, 66044
- Rekrutierung
- Lawrence Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-505-2800
- E-Mail: Stephanie.Norris@LMH.ORG
-
Hauptermittler:
- Tara L. Lin
-
Olathe, Kansas, Vereinigte Staaten, 66061
- Rekrutierung
- The University of Kansas Cancer Center - Olathe
-
Hauptermittler:
- Tara L. Lin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-1569
- E-Mail: OlatheCCResearch@kumc.edu
-
Overland Park, Kansas, Vereinigte Staaten, 66211
- Rekrutierung
- University of Kansas Hospital-Indian Creek Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Hauptermittler:
- Tara L. Lin
-
Overland Park, Kansas, Vereinigte Staaten, 66210
- Rekrutierung
- University of Kansas Cancer Center-Overland Park
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Hauptermittler:
- Tara L. Lin
-
Salina, Kansas, Vereinigte Staaten, 67401
- Rekrutierung
- Salina Regional Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-452-7038
- E-Mail: mleepers@srhc.com
-
Hauptermittler:
- Tara L. Lin
-
Topeka, Kansas, Vereinigte Staaten, 66606
- Rekrutierung
- University of Kansas Health System Saint Francis Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 785-295-8000
-
Hauptermittler:
- Tara L. Lin
-
Topeka, Kansas, Vereinigte Staaten, 66606
- Suspendiert
- Cotton O'Neil Cancer Center / Stormont Vail Health
-
Westwood, Kansas, Vereinigte Staaten, 66205
- Rekrutierung
- University of Kansas Hospital-Westwood Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Hauptermittler:
- Tara L. Lin
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- Rekrutierung
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Hauptermittler:
- Ayman Qasrawi
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Rekrutierung
- The James Graham Brown Cancer Center at University of Louisville
-
Hauptermittler:
- Mohamed M. Hegazi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-562-3429
-
Louisville, Kentucky, Vereinigte Staaten, 40245
- Rekrutierung
- UofL Health Medical Center Northeast
-
Hauptermittler:
- Mohamed M. Hegazi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-852-2755
- E-Mail: ctoinfo@louisville.edu
-
-
Louisiana
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70805
- Rekrutierung
- LSU Health Baton Rouge-North Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 225-765-7659
- E-Mail: research@ololrmc.com
-
Hauptermittler:
- Harry G. Sequeira Gross
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70808
- Rekrutierung
- Our Lady of The Lake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 225-765-7659
-
Hauptermittler:
- Harry G. Sequeira Gross
-
Baton Rouge, Louisiana, Vereinigte Staaten, 70808
- Rekrutierung
- Our Lady of the Lake Physician Group
-
Kontakt:
- Site Public Contact
- Telefonnummer: 225-765-7659
- E-Mail: research@ololrmc.com
-
Hauptermittler:
- Harry G. Sequeira Gross
-
-
Maine
-
Brunswick, Maine, Vereinigte Staaten, 04011
- Rekrutierung
- Mid Coast Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Hauptermittler:
- Pamela Egan
-
Brunswick, Maine, Vereinigte Staaten, 04011
- Rekrutierung
- MaineHealth Cancer Care and IV Therapy - Brunswick
-
Hauptermittler:
- Pamela Egan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
Portland, Maine, Vereinigte Staaten, 04102
- Rekrutierung
- MaineHealth Maine Medical Center - Portland
-
Hauptermittler:
- Pamela Egan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Rekrutierung
- MaineHealth Maine Medical Center- Scarborough
-
Hauptermittler:
- Pamela Egan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
South Portland, Maine, Vereinigte Staaten, 04106
- Rekrutierung
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Hauptermittler:
- Pamela Egan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Rekrutierung
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-955-8804
- E-Mail: jhcccro@jhmi.edu
-
Hauptermittler:
- Alexander J. Ambinder
-
Bethesda, Maryland, Vereinigte Staaten, 20889-5600
- Suspendiert
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Rekrutierung
- Dana-Farber Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-442-3324
-
Hauptermittler:
- Richard M. Stone
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Rekrutierung
- Beth Israel Deaconess Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 617-667-9925
-
Hauptermittler:
- Malgorzata McMasters
-
Boston, Massachusetts, Vereinigte Staaten, 02111
- Rekrutierung
- Tufts Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 617-636-5000
- E-Mail: ContactUsCancerCenter@TuftsMedicalCenter.org
-
Hauptermittler:
- Andreas K. Klein
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- Rekrutierung
- UMass Memorial Medical Center - University Campus
-
Hauptermittler:
- Jan Cerny
-
Kontakt:
- Site Public Contact
- Telefonnummer: 508-856-3216
- E-Mail: cancer.research@umassmed.edu
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- Rekrutierung
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Canton, Michigan, Vereinigte Staaten, 48188
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Clinton Township, Michigan, Vereinigte Staaten, 48038
- Rekrutierung
- Henry Ford Macomb Hospital-Clinton Township
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Ahmad H. Mattour
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Rekrutierung
- Wayne State University/Karmanos Cancer Institute
-
Hauptermittler:
- Vijendra Singh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-527-6266
- E-Mail: ctoadmin@karmanos.org
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Rekrutierung
- Henry Ford Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Ahmad H. Mattour
-
Farmington Hills, Michigan, Vereinigte Staaten, 48334
- Rekrutierung
- Weisberg Cancer Treatment Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-Mail: ctoadmin@karmanos.org
-
Hauptermittler:
- Vijendra Singh
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Genesys Hurley Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Hurley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Flint, Michigan, Vereinigte Staaten, 48503
- Suspendiert
- Genesee Hematology Oncology PC
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Cancer Hematology Centers - Flint
-
Kontakt:
- Site Public Contact
- Telefonnummer: 810-762-8038
- E-Mail: wstrong@ghci.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Jackson, Michigan, Vereinigte Staaten, 49201
- Rekrutierung
- Allegiance Health
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Ahmad H. Mattour
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Rekrutierung
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Novi, Michigan, Vereinigte Staaten, 48377
- Rekrutierung
- Henry Ford Medical Center-Columbus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Ahmad H. Mattour
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
West Bloomfield, Michigan, Vereinigte Staaten, 48322
- Rekrutierung
- Henry Ford West Bloomfield Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Ahmad H. Mattour
-
Ypsilanti, Michigan, Vereinigte Staaten, 48197
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Tareq Al baghdadi
-
-
Minnesota
-
Bemidji, Minnesota, Vereinigte Staaten, 56601
- Rekrutierung
- Sanford Joe Lueken Cancer Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-333-5000
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Rekrutierung
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Deer River, Minnesota, Vereinigte Staaten, 56636
- Rekrutierung
- Essentia Health - Deer River Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Rekrutierung
- Essentia Health Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Rekrutierung
- Fairview Southdale Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Rekrutierung
- Minnesota Oncology - Edina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Hibbing, Minnesota, Vereinigte Staaten, 55746
- Rekrutierung
- Essentia Health Hibbing Clinic
-
Hauptermittler:
- Bret E. Friday
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Rekrutierung
- Abbott-Northwestern Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic in Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Hauptermittler:
- James M. Foran
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Rekrutierung
- Park Nicollet Clinic - Saint Louis Park
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Rekrutierung
- Regions Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- Rekrutierung
- United Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Virginia, Minnesota, Vereinigte Staaten, 55792
- Rekrutierung
- Essentia Health Virginia Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
-
Mississippi
-
Columbus, Mississippi, Vereinigte Staaten, 39705
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Golden Triangle
-
Hauptermittler:
- Salil Goorha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Grenada, Mississippi, Vereinigte Staaten, 38901
- Rekrutierung
- Baptist Cancer Center-Grenada
-
Hauptermittler:
- Salil Goorha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
New Albany, Mississippi, Vereinigte Staaten, 38652
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Union County
-
Hauptermittler:
- Salil Goorha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Oxford, Mississippi, Vereinigte Staaten, 38655
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Hauptermittler:
- Salil Goorha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Southhaven, Mississippi, Vereinigte Staaten, 38671
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Desoto
-
Hauptermittler:
- Salil Goorha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
-
Missouri
-
City of Saint Peters, Missouri, Vereinigte Staaten, 63376
- Rekrutierung
- Siteman Cancer Center at Saint Peters Hospital
-
Hauptermittler:
- Geoffrey L. Uy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Creve Coeur, Missouri, Vereinigte Staaten, 63141
- Rekrutierung
- Siteman Cancer Center at West County Hospital
-
Hauptermittler:
- Geoffrey L. Uy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Farmington, Missouri, Vereinigte Staaten, 63640
- Rekrutierung
- Parkland Health Center - Farmington
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Kansas City, Missouri, Vereinigte Staaten, 64154
- Rekrutierung
- University of Kansas Cancer Center - North
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Hauptermittler:
- Tara L. Lin
-
Kansas City, Missouri, Vereinigte Staaten, 64108
- Rekrutierung
- University Health Truman Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-404-4375
-
Hauptermittler:
- Tara L. Lin
-
Kansas City, Missouri, Vereinigte Staaten, 64116
- Rekrutierung
- University of Kansas Cancer Center - Briarcliff
-
Hauptermittler:
- Tara L. Lin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
-
Lee's Summit, Missouri, Vereinigte Staaten, 64064
- Rekrutierung
- University of Kansas Cancer Center - Lee's Summit
-
Kontakt:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-Mail: KUCC_Navigation@kumc.edu
-
Hauptermittler:
- Tara L. Lin
-
Saint Joseph, Missouri, Vereinigte Staaten, 64506
- Suspendiert
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Vereinigte Staaten, 63670
- Rekrutierung
- Sainte Genevieve County Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University School of Medicine
-
Hauptermittler:
- Geoffrey L. Uy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
St Louis, Missouri, Vereinigte Staaten, 63129
- Rekrutierung
- Siteman Cancer Center-South County
-
Hauptermittler:
- Geoffrey L. Uy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
St Louis, Missouri, Vereinigte Staaten, 63136
- Rekrutierung
- Siteman Cancer Center at Christian Hospital
-
Hauptermittler:
- Geoffrey L. Uy
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
St Louis, Missouri, Vereinigte Staaten, 63131
- Rekrutierung
- Missouri Baptist Medical Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
St Louis, Missouri, Vereinigte Staaten, 63128
- Suspendiert
- Mercy Hospital South
-
Sullivan, Missouri, Vereinigte Staaten, 63080
- Rekrutierung
- Missouri Baptist Sullivan Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
-
Montana
-
Anaconda, Montana, Vereinigte Staaten, 59711
- Rekrutierung
- Community Hospital of Anaconda
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Billings, Montana, Vereinigte Staaten, 59101
- Rekrutierung
- Billings Clinic Cancer Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-996-2663
- E-Mail: research@billingsclinic.org
-
Bozeman, Montana, Vereinigte Staaten, 59715
- Rekrutierung
- Bozeman Health Deaconess Hospital
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Rekrutierung
- Benefis Sletten Cancer Institute
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Vereinigte Staaten, 59901
- Rekrutierung
- Logan Health Medical Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Missoula, Montana, Vereinigte Staaten, 59802
- Rekrutierung
- Saint Patrick Hospital - Community Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-327-3118
- E-Mail: amy.hanneman@providence.org
-
Hauptermittler:
- Charles W. Drescher
-
Missoula, Montana, Vereinigte Staaten, 59804
- Rekrutierung
- Community Medical Center
-
Hauptermittler:
- John M. Schallenkamp
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
-
Nebraska
-
Bellevue, Nebraska, Vereinigte Staaten, 68123
- Rekrutierung
- Nebraska Medicine-Bellevue
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-Mail: unmcrsa@unmc.edu
-
Hauptermittler:
- Michael Haddadin
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- Rekrutierung
- University of Nebraska Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-Mail: unmcrsa@unmc.edu
-
Hauptermittler:
- Michael Haddadin
-
Omaha, Nebraska, Vereinigte Staaten, 68118
- Rekrutierung
- Nebraska Medicine-Village Pointe
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-5600
-
Hauptermittler:
- Michael Haddadin
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89102
- Suspendiert
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Vereinigte Staaten, 89183
- Suspendiert
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Vereinigte Staaten, 89502
- Suspendiert
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Rekrutierung
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-Mail: cancer.research.nurse@dartmouth.edu
-
Hauptermittler:
- Raphael A. Lizcano
-
-
New Jersey
-
Basking Ridge, New Jersey, Vereinigte Staaten, 07920
- Rekrutierung
- Memorial Sloan Kettering Basking Ridge
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Aaron D. Goldberg
-
Camden, New Jersey, Vereinigte Staaten, 08103
- Rekrutierung
- Cooper Hospital University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 856-325-6757
-
Hauptermittler:
- Michael Brister
-
Livingston, New Jersey, Vereinigte Staaten, 07039
- Rekrutierung
- Cooperman Barnabas Medical Center
-
Hauptermittler:
- Neil D. Palmisiano
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-322-5200
-
Long Branch, New Jersey, Vereinigte Staaten, 07740
- Rekrutierung
- Monmouth Medical Center
-
Hauptermittler:
- Neil D. Palmisiano
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-923-6564
- E-Mail: mary.danish@rwjbh.org
-
Middletown, New Jersey, Vereinigte Staaten, 07748
- Rekrutierung
- Memorial Sloan Kettering Monmouth
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Aaron D. Goldberg
-
Montvale, New Jersey, Vereinigte Staaten, 07645
- Rekrutierung
- Memorial Sloan Kettering Bergen
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Aaron D. Goldberg
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rekrutierung
- Rutgers Cancer Institute of New Jersey
-
Hauptermittler:
- Neil D. Palmisiano
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Paramus, New Jersey, Vereinigte Staaten, 07652
- Rekrutierung
- The Valley Hospital - Luckow Pavilion
-
Hauptermittler:
- Jason Suh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 201-634-5792
- E-Mail: clinicaltrialsresearch@valleyhealth.com
-
Ridgewood, New Jersey, Vereinigte Staaten, 07450
- Rekrutierung
- Valley Health System Ridgewood Campus
-
Hauptermittler:
- Jason Suh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 201-634-5792
- E-Mail: clinicaltrialsresearch@valleyhealth.com
-
Toms River, New Jersey, Vereinigte Staaten, 08755
- Rekrutierung
- Community Medical Center
-
Hauptermittler:
- Neil D. Palmisiano
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-557-8294
- E-Mail: Lennette.Gonzales@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Rekrutierung
- University of New Mexico Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 505-925-0348
- E-Mail: HSC-ClinicalTrialInfo@salud.unm.edu
-
Hauptermittler:
- Charles Foucar
-
-
New York
-
Buffalo, New York, Vereinigte Staaten, 14263
- Rekrutierung
- Roswell Park Cancer Institute
-
Hauptermittler:
- Eunice S. Wang
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-Mail: askroswell@roswellpark.org
-
Commack, New York, Vereinigte Staaten, 11725
- Rekrutierung
- Memorial Sloan Kettering Commack
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Aaron D. Goldberg
-
Lake Success, New York, Vereinigte Staaten, 11042
- Rekrutierung
- Northwell Health/Center for Advanced Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 516-734-8896
-
Hauptermittler:
- David Chitty
-
Manhasset, New York, Vereinigte Staaten, 11030
- Rekrutierung
- North Shore University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 516-734-8896
-
Hauptermittler:
- David Chitty
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Aaron D. Goldberg
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Mount Sinai Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-824-7309
- E-Mail: CCTO@mssm.edu
-
Hauptermittler:
- Douglas A. Tremblay
-
Rochester, New York, Vereinigte Staaten, 14642
- Rekrutierung
- University of Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 585-275-5830
-
Hauptermittler:
- Jane L. Liesveld
-
Rochester, New York, Vereinigte Staaten, 14621
- Rekrutierung
- Rochester General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 585-922-3536
- E-Mail: tia.derosa@rochestergeneral.org
-
Hauptermittler:
- Maria M. Sbenghe
-
Stony Brook, New York, Vereinigte Staaten, 11794
- Rekrutierung
- Stony Brook University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-862-2215
-
Hauptermittler:
- Suhu Liu
-
Syracuse, New York, Vereinigte Staaten, 13210
- Rekrutierung
- State University of New York Upstate Medical University
-
Hauptermittler:
- Teresa C. Gentile
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-464-5476
-
The Bronx, New York, Vereinigte Staaten, 10467
- Rekrutierung
- Montefiore Medical Center - Moses Campus
-
Hauptermittler:
- Ioannis Mantzaris
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-Mail: eskwak@montefiore.org
-
Uniondale, New York, Vereinigte Staaten, 11553
- Rekrutierung
- Memorial Sloan Kettering Nassau
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Aaron D. Goldberg
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- Rekrutierung
- UNC Lineberger Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-668-0683
- E-Mail: cancerclinicaltrials@med.unc.edu
-
Hauptermittler:
- Lacey S. Williams
-
Charlotte, North Carolina, Vereinigte Staaten, 28203
- Rekrutierung
- Carolinas Medical Center/Levine Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-9376
-
Hauptermittler:
- Brittany K. Ragon
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Rekrutierung
- Novant Health Presbyterian Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 980-201-6360
- E-Mail: kashah@novanthealth.org
-
Hauptermittler:
- Patricia L. Kropf
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Rekrutierung
- Duke University Medical Center
-
Hauptermittler:
- Harry P. Erba
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-275-3853
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- Rekrutierung
- East Carolina University
-
Hauptermittler:
- Darla K. Liles
-
Kontakt:
- Site Public Contact
- Telefonnummer: 252-744-1015
- E-Mail: eubankss@ecu.edu
-
Wilmington, North Carolina, Vereinigte Staaten, 28401
- Rekrutierung
- Novant Health New Hanover Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 910-342-3000
-
Hauptermittler:
- Swaleh A. Bahamadi
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Rekrutierung
- Wake Forest University Health Sciences
-
Hauptermittler:
- Matthew J. Wieduwilt
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-713-6771
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27103
- Rekrutierung
- Novant Health Forsyth Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-718-8335
- E-Mail: pjordan@novanthealth.org
-
Hauptermittler:
- James P. Dugan
-
-
North Dakota
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Rekrutierung
- Sanford Bismarck Medical Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Rekrutierung
- Sanford Broadway Medical Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Rekrutierung
- Sanford Roger Maris Cancer Center
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-234-6161
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Rekrutierung
- Case Western Reserve University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-641-2422
- E-Mail: CTUReferral@UHhospitals.org
-
Hauptermittler:
- Benjamin K. Tomlinson
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Rekrutierung
- Ohio State University Comprehensive Cancer Center
-
Hauptermittler:
- Alice S. Mims
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-293-5066
- E-Mail: Jamesline@osumc.edu
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-Mail: ou-clinical-trials@ouhsc.edu
-
Hauptermittler:
- Manu Pandey
-
-
Oregon
-
Newberg, Oregon, Vereinigte Staaten, 97132
- Rekrutierung
- Providence Newberg Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Hauptermittler:
- Charles W. Drescher
-
Ontario, Oregon, Vereinigte Staaten, 97914
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Ontario
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Oregon City, Oregon, Vereinigte Staaten, 97045
- Rekrutierung
- Providence Willamette Falls Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Hauptermittler:
- Charles W. Drescher
-
Portland, Oregon, Vereinigte Staaten, 97213
- Rekrutierung
- Providence Portland Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Hauptermittler:
- Charles W. Drescher
-
Portland, Oregon, Vereinigte Staaten, 97225
- Rekrutierung
- Providence Saint Vincent Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Hauptermittler:
- Charles W. Drescher
-
Portland, Oregon, Vereinigte Staaten, 97239
- Suspendiert
- Oregon Health and Science University
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Rekrutierung
- Lehigh Valley Hospital-Cedar Crest
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-Mail: Morgan_M.Horton@lvhn.org
-
Hauptermittler:
- Tareq Al baghdadi
-
Danville, Pennsylvania, Vereinigte Staaten, 17822
- Rekrutierung
- Geisinger Medical Center
-
Hauptermittler:
- Joseph J. Vadakara
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-Mail: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033-0850
- Rekrutierung
- Penn State Milton S Hershey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-531-3779
- E-Mail: CTO@hmc.psu.edu
-
Hauptermittler:
- Joseph Cioccio
-
Lewistown, Pennsylvania, Vereinigte Staaten, 17044
- Rekrutierung
- Lewistown Hospital
-
Hauptermittler:
- Joseph J. Vadakara
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-242-7703
- E-Mail: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Rekrutierung
- Thomas Jefferson University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-600-9151
- E-Mail: ONCTrialNow@jefferson.edu
-
Hauptermittler:
- Margaret T. Kasner
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- University of Pennsylvania/Abramson Cancer Center
-
Hauptermittler:
- Keith W. Pratz
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-349-8245
- E-Mail: PMCancerResearch@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- Rekrutierung
- UPMC Hillman Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-647-8073
-
Hauptermittler:
- Annie P. Im
-
West Reading, Pennsylvania, Vereinigte Staaten, 19611
- Rekrutierung
- Reading Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-988-9323
-
Hauptermittler:
- Terrence P. Cescon
-
Wilkes-Barre, Pennsylvania, Vereinigte Staaten, 18711
- Rekrutierung
- Geisinger Wyoming Valley/Henry Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-Mail: HemonCCTrials@geisinger.edu
-
Hauptermittler:
- Joseph J. Vadakara
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rekrutierung
- Rhode Island Hospital
-
Hauptermittler:
- John L. Reagan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 401-444-1488
-
-
South Carolina
-
Boiling Springs, South Carolina, Vereinigte Staaten, 29316
- Rekrutierung
- Prisma Health Cancer Institute - Spartanburg
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Rekrutierung
- Medical University of South Carolina
-
Hauptermittler:
- Praneeth Baratam
-
Kontakt:
- Site Public Contact
- Telefonnummer: 843-792-9321
- E-Mail: hcc-clinical-trials@musc.edu
-
Easley, South Carolina, Vereinigte Staaten, 29640
- Rekrutierung
- Prisma Health Cancer Institute - Easley
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- Prisma Health Cancer Institute - Faris
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- Prisma Health Cancer Institute - Butternut
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29615
- Rekrutierung
- Prisma Health Cancer Institute - Eastside
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greer, South Carolina, Vereinigte Staaten, 29650
- Rekrutierung
- Prisma Health Cancer Institute - Greer
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Seneca, South Carolina, Vereinigte Staaten, 29672
- Rekrutierung
- Prisma Health Cancer Institute - Seneca
-
Hauptermittler:
- Suzanne R. Fanning
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57104
- Rekrutierung
- Sanford Cancer Center Oncology Clinic
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-Mail: OncologyClinicTrialsSF@sanfordhealth.org
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Rekrutierung
- Sanford USD Medical Center - Sioux Falls
-
Hauptermittler:
- Daniel Almquist
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-Mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
-
Tennessee
-
Collierville, Tennessee, Vereinigte Staaten, 38017
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Hauptermittler:
- Salil Goorha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
Knoxville, Tennessee, Vereinigte Staaten, 37920
- Suspendiert
- University of Tennessee - Knoxville
-
Memphis, Tennessee, Vereinigte Staaten, 38120
- Rekrutierung
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Hauptermittler:
- Salil Goorha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 901-226-1366
- E-Mail: BCCclintrials@bmhcc.org
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-798-1354
- E-Mail: burton@bcm.edu
-
Hauptermittler:
- Tareq Abuasab
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Ben Taub General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-873-2000
-
Hauptermittler:
- Tareq Abuasab
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Rekrutierung
- Huntsman Cancer Institute/University of Utah
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-424-2100
- E-Mail: cancerinfo@hci.utah.edu
-
Hauptermittler:
- Paul J. Shami
-
Salt Lake City, Utah, Vereinigte Staaten, 84148
- Rekrutierung
- George E Wahlen Department of Veterans Affairs Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 801-582-1565
-
Hauptermittler:
- Tsewang Tashi
-
-
Vermont
-
Burlington, Vermont, Vereinigte Staaten, 05401
- Rekrutierung
- University of Vermont Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-4101
- E-Mail: rpo@uvm.edu
-
Hauptermittler:
- Diego A. Adrianzen Herrera
-
Burlington, Vermont, Vereinigte Staaten, 05405
- Rekrutierung
- University of Vermont and State Agricultural College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-8990
- E-Mail: rpo@uvm.edu
-
Hauptermittler:
- Diego A. Adrianzen Herrera
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- Rekrutierung
- University of Virginia Cancer Center
-
Hauptermittler:
- Daniel R. Reed
-
Kontakt:
- Site Public Contact
- Telefonnummer: 434-243-6303
- E-Mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- Inova Schar Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 703-720-5210
- E-Mail: Stephanie.VanBebber@inova.org
-
Hauptermittler:
- Danielle A. Shafer
-
Falls Church, Virginia, Vereinigte Staaten, 22042
- Rekrutierung
- Inova Fairfax Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 703-208-6650
- E-Mail: Stephanie.VanBebber@inova.org
-
Hauptermittler:
- Danielle A. Shafer
-
Richmond, Virginia, Vereinigte Staaten, 23298
- Rekrutierung
- VCU Massey Comprehensive Cancer Center
-
Hauptermittler:
- Keri R. Maher
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-Mail: CTOclinops@vcu.edu
-
-
Washington
-
Edmonds, Washington, Vereinigte Staaten, 98026
- Rekrutierung
- Swedish Cancer Institute-Edmonds
-
Hauptermittler:
- Charles W. Drescher
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-215-2343
- E-Mail: PCRC-NCORP@Swedish.org
-
Issaquah, Washington, Vereinigte Staaten, 98029
- Rekrutierung
- Swedish Cancer Institute-Issaquah
-
Hauptermittler:
- Charles W. Drescher
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-215-2343
- E-Mail: PCRC-NCORP@Swedish.org
-
Seattle, Washington, Vereinigte Staaten, 98122
- Rekrutierung
- Swedish Medical Center-First Hill
-
Hauptermittler:
- Charles W. Drescher
-
Kontakt:
- Site Public Contact
- Telefonnummer: 206-215-2343
- E-Mail: PCRC-NCORP@Swedish.org
-
Seattle, Washington, Vereinigte Staaten, 98195
- Rekrutierung
- University of Washington Medical Center - Montlake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Hauptermittler:
- Jacob S. Appelbaum
-
Seattle, Washington, Vereinigte Staaten, 98109
- Rekrutierung
- Fred Hutchinson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Hauptermittler:
- Jacob S. Appelbaum
-
-
Wisconsin
-
Appleton, Wisconsin, Vereinigte Staaten, 54911
- Rekrutierung
- ThedaCare Regional Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-364-3604
- E-Mail: ResearchDept@thedacare.org
-
Hauptermittler:
- Yazhini Vallatharasu
-
Ashland, Wisconsin, Vereinigte Staaten, 54806
- Rekrutierung
- Duluth Clinic Ashland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-Mail: CancerTrials@EssentiaHealth.org
-
Hauptermittler:
- Bret E. Friday
-
Burlington, Wisconsin, Vereinigte Staaten, 53105
- Rekrutierung
- Aurora Cancer Care-Southern Lakes VLCC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Cudahy, Wisconsin, Vereinigte Staaten, 53110
- Rekrutierung
- Aurora Saint Luke's South Shore
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Eau Claire, Wisconsin, Vereinigte Staaten, 54701
- Rekrutierung
- Marshfield Medical Center-EC Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
Germantown, Wisconsin, Vereinigte Staaten, 53022
- Rekrutierung
- Aurora Health Care Germantown Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Grafton, Wisconsin, Vereinigte Staaten, 53024
- Rekrutierung
- Aurora Cancer Care-Grafton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Vereinigte Staaten, 54311
- Rekrutierung
- Aurora BayCare Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Vereinigte Staaten, 54301
- Rekrutierung
- Saint Vincent Hospital Cancer Center Green Bay
-
Hauptermittler:
- Matthew L. Ryan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: WI_research_admin@hshs.org
-
Green Bay, Wisconsin, Vereinigte Staaten, 54303
- Rekrutierung
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Hauptermittler:
- Matthew L. Ryan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: wi_research_admin@hshs.org
-
Janesville, Wisconsin, Vereinigte Staaten, 53548
- Rekrutierung
- Mercyhealth Hospital and Cancer Center - Janesville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 608-756-6871
- E-Mail: oncologyclinicaltrials@mhemail.org
-
Hauptermittler:
- Emily G. Robinson
-
Kenosha, Wisconsin, Vereinigte Staaten, 53142
- Rekrutierung
- Aurora Cancer Care-Kenosha South
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
La Crosse, Wisconsin, Vereinigte Staaten, 54601
- Rekrutierung
- Gundersen Lutheran Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 608-775-2385
- E-Mail: cancerctr@gundersenhealth.org
-
Hauptermittler:
- David E. Marinier
-
Madison, Wisconsin, Vereinigte Staaten, 53705
- Rekrutierung
- William S Middleton VA Medical Center
-
Hauptermittler:
- Christopher D. Fletcher
-
Kontakt:
- Site Public Contact
- Telefonnummer: 17007 608-256-1901
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- Rekrutierung
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Hauptermittler:
- Kieran D. Sahasrabudhe
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-Mail: clinicaltrials@cancer.wisc.edu
-
Madison, Wisconsin, Vereinigte Staaten, 53718
- Rekrutierung
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Hauptermittler:
- Kieran D. Sahasrabudhe
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-Mail: clinicaltrials@cancer.wisc.edu
-
Marinette, Wisconsin, Vereinigte Staaten, 54143
- Rekrutierung
- Aurora Bay Area Medical Group-Marinette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Rekrutierung
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
Menomonee Falls, Wisconsin, Vereinigte Staaten, 53051
- Rekrutierung
- Froedtert Menomonee Falls Hospital
-
Hauptermittler:
- Ehab L. Atallah
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-257-5100
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53209
- Rekrutierung
- Aurora Cancer Care-Milwaukee
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53215
- Rekrutierung
- Aurora Saint Luke's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Rekrutierung
- Medical College of Wisconsin
-
Hauptermittler:
- Ehab L. Atallah
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-805-3666
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53233
- Rekrutierung
- Aurora Sinai Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Minocqua, Wisconsin, Vereinigte Staaten, 54548
- Rekrutierung
- Marshfield Medical Center - Minocqua
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
Mukwonago, Wisconsin, Vereinigte Staaten, 53149
- Rekrutierung
- ProHealth D N Greenwald Center
-
Kontakt:
- Site Public Contact
- E-Mail: research.institute@phci.org
-
Hauptermittler:
- Timothy R. Wassenaar
-
New Berlin, Wisconsin, Vereinigte Staaten, 53151
- Rekrutierung
- Froedtert and MCW Moorland Reserve Health Center
-
Hauptermittler:
- Ehab L. Atallah
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-805-0505
-
Oak Creek, Wisconsin, Vereinigte Staaten, 53154
- Rekrutierung
- Drexel Town Square Health Center
-
Hauptermittler:
- Ehab L. Atallah
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-805-0505
-
Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
- Rekrutierung
- ProHealth Oconomowoc Memorial Hospital
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-7878
-
Oconto Falls, Wisconsin, Vereinigte Staaten, 54154
- Rekrutierung
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Hauptermittler:
- Matthew L. Ryan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: WI_research_admin@hshs.org
-
Oshkosh, Wisconsin, Vereinigte Staaten, 54904
- Rekrutierung
- Vince Lombardi Cancer Clinic - Oshkosh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Racine, Wisconsin, Vereinigte Staaten, 53406
- Rekrutierung
- Aurora Cancer Care-Racine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Rice Lake, Wisconsin, Vereinigte Staaten, 54868
- Rekrutierung
- Marshfield Medical Center-Rice Lake
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
Sheboygan, Wisconsin, Vereinigte Staaten, 53081
- Rekrutierung
- Vince Lombardi Cancer Clinic-Sheboygan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Sheboygan, Wisconsin, Vereinigte Staaten, 53081
- Rekrutierung
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Hauptermittler:
- Matthew L. Ryan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: wi_research_admin@hshs.org
-
Stevens Point, Wisconsin, Vereinigte Staaten, 54482
- Rekrutierung
- Marshfield Medical Center-River Region at Stevens Point
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
Sturgeon Bay, Wisconsin, Vereinigte Staaten, 54235-1495
- Rekrutierung
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Hauptermittler:
- Matthew L. Ryan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: wi_research_admin@hshs.org
-
Summit, Wisconsin, Vereinigte Staaten, 53066
- Rekrutierung
- Aurora Medical Center in Summit
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Two Rivers, Wisconsin, Vereinigte Staaten, 54241
- Rekrutierung
- Vince Lombardi Cancer Clinic-Two Rivers
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- Rekrutierung
- ProHealth Waukesha Memorial Hospital
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-7632
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- Rekrutierung
- UW Cancer Center at ProHealth Care
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-5539
- E-Mail: Chanda.miller@phci.org
-
Wauwatosa, Wisconsin, Vereinigte Staaten, 53226
- Rekrutierung
- Aurora Cancer Care-Milwaukee West
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
West Allis, Wisconsin, Vereinigte Staaten, 53227
- Rekrutierung
- Aurora West Allis Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Thomas J. Saphner
-
West Bend, Wisconsin, Vereinigte Staaten, 53095
- Rekrutierung
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Hauptermittler:
- Ehab L. Atallah
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-805-0505
-
Weston, Wisconsin, Vereinigte Staaten, 54476
- Rekrutierung
- Marshfield Medical Center - Weston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Adedayo A. Onitilo
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS.
-
Participants must be >= 18 years of age.
-
Participants must not have received prior anti-cancer therapy for AML or MDS.
- Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
- Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m^2 of cytarabine, which is allowed for urgent cytoreduction.
-
Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of exposure.
- Note: Participants receiving hydroxyurea prior to treatment substudy or TAP assignment must agree to discontinue hydroxyurea within 24 hours before beginning substudy or TAP treatment.
-
Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy
- Note: active hormonal therapy is allowed
-
Participants must have a Zubrod Performance Status evaluation within 28 days prior to registration.
-
Participants must agree to have translational medicine specimens submitted.
-
Participants must be offered the opportunity to participate in specimen banking.
- Note: Specimens must be collected and submitted following the initial paper-based process and subsequently via the Precision Medicine Specimen Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP.
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.
- Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
-
The master screening and reassessment protocol (MSRP) should only be used in sites where the relevant AML treatment substudies are open or if the site is willing to follow the MSRP Tier Advancement Pathway (TAP) for patients in the event that the site does not have the relevant study open and transfer to another site that does have the study open. For example, if a site does not have a myeloMATCH Tier 1 study for older AML open for enrollment, such older AML patients should only be consented for the MSRP if the site is willing to treat the patient with standard of care on TAP or is willing to transfer the patient to a center with a study open that the patient would otherwise match to.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Screening
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: MM1MDS-A01 Regimen 1 (ASTX727)
Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 2. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression. |
Undergo bone marrow biopsy
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1MDS-A01 Regimen 2 (ASTX727, enasidenib)
Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression. |
Undergo bone marrow biopsy
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: MM1MDS-CTG02 Arm 1 (Luspatercept)
Patients receive luspatercept SC on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given SC
Andere Namen:
|
|
Experimental: MM1MDS-CTG02 Arm 2 (Luspatercept with epoetin alfa)
Patients receive luspatercept SC on day 1 and epoetin alfa SC QW for each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Given SC
Andere Namen:
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given SC
Andere Namen:
|
|
Experimental: MM1MDS-CTG02 Arm 3 (Luspatercept and emavusertib)
Patients receive luspatercept SC on day 1 and emavusertib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given SC
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 of each cycle and venetoclax PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial. |
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Given IV or SC
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial. |
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Given IV or SC
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days 1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until bone marrow assessment shows at least an MLFS response or better ("better" defined as CR, CRi, CRh), in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days 1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and aspiration as well as blood sample collection on the trial. |
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Given IV or SC
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given PO
Andere Namen:
|
|
Aktiver Komparator: MM1OA-MDS-A05 Cohort A, Arm 1 (ASTX727, venetoclax)
Patients receive ASTX727 PO QD on days 1-5 of each cycle and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1OA-MDS-A05 Cohort A,Arm 2 (ASTX727,venetoclax,olutasidenib)
Patients receive ASTX727 PO QD on days 1-5 of each cycle, venetoclax PO QD on days 1-28 of each cycle, and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR, CRh, or CRi after cycle 4 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: MM1OA-MDS-A05 Cohort B, Arm 3 (ASTX727, olutasidenib)
Patients receive ASTX727 PO QD on days 1-5 of each cycle and olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given PO
Andere Namen:
|
|
Aktiver Komparator: MM1OA-MDS-A05 Cohort B, Arm 4 (ASTX727)
Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients without CR after cycle 6 may then cross-over to Arm 3. Patients with CR, as well as patients without CR but deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1OA-MDS-A05 Cohort C (olutasidenib)
Patients receive olutasidenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit after cycle 6 continue treatment cycles every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow biopsy/aspiration and collection of blood samples throughout the trial. |
Undergo bone marrow biopsy
Andere Namen:
Undergo bone marrow aspiration Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given PO
Andere Namen:
|
|
Aktiver Komparator: MM1OA-S03 Arm 1 (ASTX727, venetoclax)
Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial. |
Undergo bone marrow biopsy
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)
Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, bone marrow aspiration, and bone marrow biopsy throughout the trial. |
Undergo bone marrow biopsy
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given PO
Andere Namen:
|
|
Aktiver Komparator: MM1OA-S04 Arm 1 (ASTX727 with standard duration venetoclax)
Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Given PO
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1OA-S04 Arm 2 (ASTX727 with shorter duration venetoclax)
Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-14 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and blood sample collection throughout the study. |
Undergo bone marrow aspiration Given PO
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Aktiver Komparator: MM1YA-A04 Regimen 1 (gemtuzumab ozogamicin, chemotherapy)
Patients receive gemtuzumab ozogamicin IV on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given IV
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Receive SOC treatment
Andere Namen:
|
|
Experimental: MM1YA-A04 Regimen 2 (venetoclax, chemotherapy)
Patients receive venetoclax PO QD on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study. |
Given IV
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given IV
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Receive SOC treatment
Andere Namen:
|
|
Experimental: MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)
Patients receive daunorubicin IV on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax PO QD on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening. |
Given IV
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given IV
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1YA-CTG01 Arm II (azacitidine, venetoclax)
Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening. |
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Given IV or SC
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Aktiver Komparator: MM1YA-CTG01 Arm III (daunorubicin, cytarabine)
Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening. |
Given IV
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given IV
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1YA-EA05 Arm A (cytarabine, daunorubicin, quizartinib)
See Detailed Description. |
Given IV
Andere Namen:
Undergo bone marrow biopsy
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given IV
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: MM1YA-EA05 Arm B (azacitidine, venetoclax, quizartinib)
See Detailed Description. |
Undergo bone marrow biopsy
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Given IV or SC
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given PO
Andere Namen:
|
|
Aktiver Komparator: MM1YA-S01 Arm I (cytarabine, daunorubicin)
Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1-2. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Given IV
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given IV
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)
Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Given IV
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given IV
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1YA-S01 Arm III (azacitidine, venetoclax)
Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Given IV or SC
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1YA-S01 Arm IV (Vyxeos)
Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given IV
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: MM1YA-S01 Arm V (Vyxeos, venetoclax)
Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days 1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients may receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and collection of blood throughout the trial. |
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given PO
Andere Namen:
Given IV
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Aktiver Komparator: MM2YA-EA01 Arm A (cytarabine)
Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Given IV
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
|
|
Experimental: MM2YA-EA01 Arm B (cytarabine, venetoclax)
Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Given IV
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: MM2YA-EA01 Arm C (Vyxeos, venetoclax)
Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Given IV
Andere Namen:
|
|
Experimental: MM2YA-EA01 Arm D (azacitidine, venetoclax)
Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated. |
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo biopsy
Andere Namen:
Given PO
Andere Namen:
Given IV or SC
Andere Namen:
|
|
Experimental: MM3TCT-A03 Conditioning 1A (matched donors with venetoclax)
Patients receive venetoclax PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Andere Namen:
Undergo CT
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo PET
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Given IV
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given IV
Andere Namen:
Undergo chest x-ray
Andere Namen:
Given IV
Andere Namen:
|
|
Placebo-Komparator: MM3TCT-A03 Conditioning 1B (matched donors with placebo)
Patients receive placebo PO QD on days -10 to -2, fludarabine IV on days -6 or -5 to -2 and busulfan IV on days -3 to -2 or BID on days -5 to -2 or melphalan IV on day -2. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Andere Namen:
Undergo CT
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo PET
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given PO Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given IV
Andere Namen:
Undergo chest x-ray
Andere Namen:
Given IV
Andere Namen:
|
|
Experimental: MM3TCT-A03 Conditioning 2A (haplo/mismatch with venetoclax)
Patients receive venetoclax PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Andere Namen:
Undergo CT
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo PET
Andere Namen:
Given PO
Andere Namen:
Given IV
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given IV
Andere Namen:
Undergo chest x-ray
Andere Namen:
Given IV
Andere Namen:
Undergo total body irradiation
Andere Namen:
|
|
Placebo-Komparator: MM3TCT-A03 Conditioning 2B (haplo/mismatch with placebo)
Patients receive placebo PO QD on days -10 to -2, melphalan IV on day -6, fludarabine IV on days -5 to -2 and undergo total body irradiation once on day -1. Patients then receive hematopoietic cell transplant IV on day 0. Treatment is given in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray, echocardiography or MUGA during screening, and bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Andere Namen:
Undergo CT
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo PET
Andere Namen:
Given IV
Andere Namen:
Given PO Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
Given IV
Andere Namen:
Undergo chest x-ray
Andere Namen:
Given IV
Andere Namen:
Undergo total body irradiation
Andere Namen:
|
|
Experimental: MM3TCT-A03 Maintenance I (venetoclax)
Patients receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Andere Namen:
Undergo CT
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo PET
Andere Namen:
Given PO
Andere Namen:
Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Placebo-Komparator: MM3TCT-A03 Maintenance II (placebo)
Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year post transplant (9 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow biopsy and blood, urine and buccal swab collection throughout the study. Patients may also undergo PET scan and/or CT scan throughout the study. |
Undergo bone marrow biopsy
Andere Namen:
Undergo CT
Andere Namen:
Undergo PET
Andere Namen:
Given PO Undergo collection of blood, urine, and/or buccal swab samples
Andere Namen:
|
|
Experimental: Screening (mutation carrier screening)
Patients undergo bone marrow aspiration and collection of blood on study. Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are then assigned to a specific substudy containing a therapy targeted to the patient's mutational profile. If there is no targetable mutation, the patient is placed on a substudy testing novel combinations that do not contain a target-specific drug. Patients who are not eligible for any MYELOMATCH substudy are assigned to TAP. |
Undergo rapid genetic testing |
|
Experimental: TAP (SOC treatment, mutation carrier screening)
Patients continue SOC treatment and undergo continued bone marrow aspiration and blood collection for possible future substudy assignment. |
Receive SOC treatment
Andere Namen:
Undergo rapid genetic testing |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment
Zeitfenster: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will evaluate the feasibility of MATCHBox generating all data needed for assignment to a myeloMATCH clinical trial or determination that no assignment is available, within 72 hours of MDNet receipt of specimens for initial therapy and within 10 days for subsequent therapy. For first treatment assignment and separately for each subsequent treatment assignments: every 50 participants for the first 250 participants and then every 100 participants thereafter, the proportion of participants (cumulative and new participants since prior analysis) with all MDNet data needed to determine a treatment assignment within 72 hours for first assignment and 10 days for subsequent assignments after the MDNet receives specimens will be tallied. |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to MDNet generating all data required for treatment substudy or TAP assignment
Zeitfenster: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Time to treatment substudy or TAP assignment
Zeitfenster: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Percent assigned to a myeloMATCH clinical trial
Zeitfenster: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Percent of screened participants who register to a treatment substudy
Zeitfenster: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Assignment to higher tier treatment substudies within myeloMATCH
Zeitfenster: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Adverse events
Zeitfenster: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Minimal residual disease (MRD) response
Zeitfenster: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
MRD response is based on flow cytometry studies performed by the MDnet. |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Time-to-event outcomes for exploratory analysis
Zeitfenster: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Will be assessed within each tier of clinical trials, within each clinical basket of clinical trials, and over time (since last report and in 6 month intervals from study opening). |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
|
Performance status
Zeitfenster: Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Participants will be graded according to the Zubrod performance status scale. |
Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Jerald P Radich, SWOG Cancer Research Network
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Leukämie, Myeloid
- Erkrankungen des Knochenmarks
- Leukämie
- Hämische und lymphatische Krankheiten
- Leukämie, myeloisch, akut
- Myelodysplastische Syndrome
- Myeloproliferative Erkrankungen
- Verwaltung des Gesundheitswesens
- Qualität, Zugang und Bewertung im Gesundheitswesen
- Peptide
- Aminosäuren, Peptide und Proteine
- Proteine
- Schwefelverbindungen
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Pharmazeutische Präparate
- Untersuchungstechniken
- Therapeutika
- Dosierungsformen
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Chirurgische Eingriffe, operativ
- Routen der Arzneimittelverwaltung
- Arzneimitteltherapie
- Zytologische Techniken
- Nukleinsäuren, Nukleotide und Nukleoside
- Zytodiagnose
- Kohlenwasserstoffe, acyclisch
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Biologische Faktoren
- Qualität der Gesundheitsversorgung
- Kohlenhydrate
- Physikalische Phänomene
- Polycyclische aromatische Kohlenwasserstoffe
- Kohlenwasserstoffe, aromatisch
- Polycyclische Verbindungen
- Glykoside
- Qualitätsindikatoren, Gesundheitsversorgung
- Transplantation
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Aminosäuren
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Alkane
- Diagnosetechniken, chirurgisch
- Biomedizinische und Zahnmaterialien
- Herstellte Materialien
- Technologie, Industrie und Landwirtschaft
- Alkohole
- Chemie -Techniken, analytisch
- Butylenglykole
- Glykole
- Mesylate
- Alkanesulfonate
- Alkanesulfonsäuren
- Sulfonsäuren
- Schwefelsäuren
- Spektrumanalyse
- Stickstoffsenfverbindungen
- Senfverbindungen
- Kohlenwasserstoffe, halogeniert
- Aza -Verbindungen
- Nukleoside
- Ribonukleoside
- Interzelluläre Signalpeptide und Proteine
- Arabinonukleosides
- Anthracyclines
- Naphthatene
- Aminoglykoside
- Glykoproteine
- Glykoconjugate
- Elektromagnetische Phänomene
- Magnetische Phänomene
- Strahlentherapie
- Zelltransplantation
- Zell- und Gewebe-basierte Therapie
- Biologische Therapie
- Phenylalanin
- Aminosäuren, aromatisch
- Aminosäuren, zyklisch
- Elektromagnetische Strahlung
- Strahlung
- Strahlung, ionisieren
- Richtlinien als Thema
- Qualitätssicherung, Gesundheitsversorgung
- Koloniestimulierende Faktoren
- Hämatopoetische Zellwachstumsfaktoren
- Zytokine
- Calicheamicins
- Membranen, künstlich
- Drogenträger
- Biomimetische Materialien
- Erythropoietin
- Epoetin Alfa
- Gemtuzumab
- Cytarabin
- Melphalan
- Azacitidin
- Daunorubicin
- Busulfan
- Injektionen
- Sorgfalt
- Biopsie
- Handhabung von Proben
- Magnetresonanzspektroskopie
- Fludarabine
- Venetoklax
- Stammzelltransplantation
- Decitabin- und Cedazuridin -Arzneimittelkombination
- Röntgenaufnahmen
- Üben Sie Richtlinien als Thema
- Ganzkörperbestrahlung
- Enasidenib
- Quizartinib
- Gilteritinib
- CPX-351
- Liposomen
- CA-4948
- Olutasidenib
- LUSPATERAPTE
Andere Studien-ID-Nummern
- NCI-2022-07006
- U10CA180888 (US NIH Stipendium/Vertrag)
- NCI-2022-07006 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- MYELOMATCH (Andere Kennung: CTEP)
- MYELOMATCH (Andere Kennung: SWOG)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .